MSB $1 Party, page-859

Trading parcels bought on 30 June @ $0.61 are now up around my favorite number - 69% ... not a bad effort for 21 days


I have always said @eyeswideopen a CHF partnership is what will unfold for Rex-L and after reading those results on the 19th July I believe it will happen by end of 2022 .....


I have raised the issue previously that if the Cephalon deal for $350 million was negotiated over a decade ago off the back of phase 2 results, what will big pharma pay to be a part of this now given the wealth of new and supporting data even if an additional phase 3 trial is required ?


One single treatment with huge benefits years on and one single treatment showing great results over and above SOC - just sayin'


If SI and Co. can't negotiate a great Global CHF partnership deal off the back of these results and latest data, then we are in serious trouble

GLTAH


https://www.genengnews.com/topics/t...last $130,adult stem cell technology platform.

Cephalon Shells Out $350M to Commercialize Mesoblast Stem Cell Therapies


Deal includes $130 million up front and a $220 million equity payment for a 19.99% stake in Aussie firm.

Cephalon is paying Mesoblast $130 million up front and will make a $220 million equity investment in the Australian firm as part of a collaboration to develop and commercialize adult mesenchymal precursor stem cell (MPC) therapies based on Mesoblast’s adult stem cell technology platform.